悦心健康(002162.SZ):斯米克工業擬以集中競價繼續減持不超2%的股份
格隆匯12月20日丨悦心健康(002162.SZ)公佈,公司於2022年9月22日披露了《關於控股股東減持股份計劃數量過半暨減持比例達1%的進展公吿》(公吿編號:2022-033)。截至2022年9月20日,上述減持計劃的減持數量已達50%,且減持股份比例達到公司股份總數的1%。自公司2022年9月22日披露進展公吿至2022年12月19日,斯米克工業通過集中競價交易方式累計減持公司股份926.5萬股,佔公司股份總數1%。同時上述股份減持計劃實施完畢,實際減持數量未超過計劃減持股份數量。
後續減持計劃:斯米克工業計劃在公吿披露之日起15個交易日後的6個月內,通過集中競價交易方式減持公司股份不超過1853萬股,佔公司股份總數2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.